ARID1A and neoplasm: Additionally, ARID1A depletion sensitizes cell drug response to JQ1 and other two relevant clinical BET inhibitors, suggesting a critical role of this complex in mediating ERα action and results showed ARID1A and several SWI/SNF components, including BRG1and BRM as physical interactors of the receptor even in the surgical tumor tissue.